AKTX
Akari Therapeutics Plc
Key Financials
Net Income
$-17298000
↑ 12.6%
EPS (Diluted)
$0.00
NaN%
Total Liabilities
$19.6M
↓ 30.9%
Total Assets
$47.9M
↓ 5.3%
Cash & Equivalents
$0.00
↓ 100.0%
Shareholders' Equity
$28.3M
↑ 27.4%
Operating Income
$-17275000
↑ 20.2%
Operating Cash Flow
$-10568000.00
↑ 15.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 8/13/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| SCHEDULE 13G | 8/12/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| EFFECT | 7/13/2026 | View on SEC |
| S-3/A | 7/10/2026 | View on SEC |
| S-3/A | 7/8/2026 | View on SEC |
| EFFECT | 7/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AKTX |
| Company Name | Akari Therapeutics Plc |
| CIK | 1541157 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | X0 |
| Phone | (929) 274-7510 |